老年乳腺癌患者治疗依从性和耐受性选择根治性放疗方案的老年学决定因素:GERABEL 研究的结果。

IF 3 3区 医学 Q3 GERIATRICS & GERONTOLOGY Journal of geriatric oncology Pub Date : 2024-11-08 DOI:10.1016/j.jgo.2024.102147
Elisabeth Daguenet, Emmanuel Chamorey, Omar Jmour, Grégoire Pigné, Caroline Chung Kim Yuen, Emilie Gadéa-Deschamps, Elodie Guillaume, Claire Bosacki, Blandine De Lavigerie, Rachid Laassami, Nicolas Magné
{"title":"老年乳腺癌患者治疗依从性和耐受性选择根治性放疗方案的老年学决定因素:GERABEL 研究的结果。","authors":"Elisabeth Daguenet, Emmanuel Chamorey, Omar Jmour, Grégoire Pigné, Caroline Chung Kim Yuen, Emilie Gadéa-Deschamps, Elodie Guillaume, Claire Bosacki, Blandine De Lavigerie, Rachid Laassami, Nicolas Magné","doi":"10.1016/j.jgo.2024.102147","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Chronological and functional aging complicates care in older patients, and therapeutic decisions need to consider individual needs to minimise morbidity and mortality. Therapeutic decisions should be guided by a multidisciplinary geriatric assessment, allowing a complete assessment of physical and functional performance. In this context, the GERABEL study aimed to orientate the irradiation strategy based on a detailed oncogeriatric assessment in women more than 70 years old with breast cancer.</p><p><strong>Materials and methods: </strong>This was a multicentre clinical trial conducted between January 2017 and June 2021. The oncogeriatric assessment comprised seven questionnaires (activities of daily living [ADL], instrumental ADL, Mini-Mental State Examination, mini Geriatric Depression Scale, Mini-Nutritional Assessment, Cumulative Illness Rating Scale-Geriatric, and Timed Up and Go) to determine a predictive score. Irradiation regimen was assigned according to oncogeriatric score: normofractionated - NF (score range, 160-200), hypofractionated - HF (score range, 159-120), or high-dose hypofractionated - HDHF (score ≤ 119). Endpoints were the overall tolerance to treatment, using the oncogeriatric score as a proxy at six months post-treatment, and compliance.</p><p><strong>Results: </strong>After oncogeriatric assessment at baseline, 177 patients were treated with a NF regimen, 24 with a HF regimen, and four with a HDHF regimen. Tolerance was excellent in the three groups, as no decrease of more than 20 % in the oncogeriatric score was noted at six months post-treatment. More generally, 68 % and 73 % of patients reported an improvement of the oncogeriatric score at two months and six months post-treatment, respectively. Only four treatment interruptions were observed and quality-of-life was well-conserved. In the hypo fractionated groups, short-term toxicities were not increased and no impact was noted on compliance.</p><p><strong>Discussion: </strong>Decision-making guidance for irradiation schemes in breast cancer according to oncogeriatric determinants was successful in older patients, who tolerated treatment well and, overall, had a preserved general condition.</p>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":" ","pages":"102147"},"PeriodicalIF":3.0000,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Geriatric determinants of curative radiotherapy scheme choice for older adults with breast cancer treatment compliance and tolerance: Results from the GERABEL study.\",\"authors\":\"Elisabeth Daguenet, Emmanuel Chamorey, Omar Jmour, Grégoire Pigné, Caroline Chung Kim Yuen, Emilie Gadéa-Deschamps, Elodie Guillaume, Claire Bosacki, Blandine De Lavigerie, Rachid Laassami, Nicolas Magné\",\"doi\":\"10.1016/j.jgo.2024.102147\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Chronological and functional aging complicates care in older patients, and therapeutic decisions need to consider individual needs to minimise morbidity and mortality. Therapeutic decisions should be guided by a multidisciplinary geriatric assessment, allowing a complete assessment of physical and functional performance. In this context, the GERABEL study aimed to orientate the irradiation strategy based on a detailed oncogeriatric assessment in women more than 70 years old with breast cancer.</p><p><strong>Materials and methods: </strong>This was a multicentre clinical trial conducted between January 2017 and June 2021. The oncogeriatric assessment comprised seven questionnaires (activities of daily living [ADL], instrumental ADL, Mini-Mental State Examination, mini Geriatric Depression Scale, Mini-Nutritional Assessment, Cumulative Illness Rating Scale-Geriatric, and Timed Up and Go) to determine a predictive score. Irradiation regimen was assigned according to oncogeriatric score: normofractionated - NF (score range, 160-200), hypofractionated - HF (score range, 159-120), or high-dose hypofractionated - HDHF (score ≤ 119). Endpoints were the overall tolerance to treatment, using the oncogeriatric score as a proxy at six months post-treatment, and compliance.</p><p><strong>Results: </strong>After oncogeriatric assessment at baseline, 177 patients were treated with a NF regimen, 24 with a HF regimen, and four with a HDHF regimen. Tolerance was excellent in the three groups, as no decrease of more than 20 % in the oncogeriatric score was noted at six months post-treatment. More generally, 68 % and 73 % of patients reported an improvement of the oncogeriatric score at two months and six months post-treatment, respectively. Only four treatment interruptions were observed and quality-of-life was well-conserved. In the hypo fractionated groups, short-term toxicities were not increased and no impact was noted on compliance.</p><p><strong>Discussion: </strong>Decision-making guidance for irradiation schemes in breast cancer according to oncogeriatric determinants was successful in older patients, who tolerated treatment well and, overall, had a preserved general condition.</p>\",\"PeriodicalId\":15943,\"journal\":{\"name\":\"Journal of geriatric oncology\",\"volume\":\" \",\"pages\":\"102147\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2024-11-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of geriatric oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.jgo.2024.102147\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"GERIATRICS & GERONTOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of geriatric oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jgo.2024.102147","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"GERIATRICS & GERONTOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

导言:年龄和功能的老化使老年患者的护理变得复杂,治疗决策需要考虑个人需求,以最大限度地降低发病率和死亡率。治疗决策应在多学科老年病学评估的指导下做出,以便对身体和功能表现进行全面评估。在这种情况下,GERABEL 研究旨在根据对 70 岁以上女性乳腺癌患者进行的详细老年肿瘤评估来确定照射策略:这是一项多中心临床试验,于2017年1月至2021年6月期间进行。肿瘤老年学评估包括七份问卷(日常生活活动[ADL]、工具性日常生活活动、迷你精神状态检查、迷你老年抑郁量表、迷你营养评估、老年累积疾病评分量表和定时起立行走),以确定预测得分。放疗方案根据老年肿瘤学评分进行分配:常剂量--NF(评分范围为160-200分)、低剂量--HF(评分范围为159-120分)或高剂量低剂量--HDHF(评分≤119分)。终点是治疗后六个月以肿瘤老年学评分为代表的总体治疗耐受性和依从性:结果:经过基线老年肿瘤学评估,177 名患者接受了 NF 方案治疗,24 名患者接受了 HF 方案治疗,4 名患者接受了 HDHF 方案治疗。三组患者的耐受性都很好,治疗后六个月的老年肿瘤评分下降幅度均未超过 20%。更广泛地说,分别有 68% 和 73% 的患者在治疗后两个月和六个月报告说老年肿瘤评分有所改善。只有四例患者中断了治疗,生活质量得到了很好的保证。在低分化组中,短期毒性没有增加,对依从性也没有影响:讨论:根据老年肿瘤学决定因素为乳腺癌照射方案提供决策指导对老年患者是成功的,他们能很好地耐受治疗,而且总体上总体状况良好。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Geriatric determinants of curative radiotherapy scheme choice for older adults with breast cancer treatment compliance and tolerance: Results from the GERABEL study.

Introduction: Chronological and functional aging complicates care in older patients, and therapeutic decisions need to consider individual needs to minimise morbidity and mortality. Therapeutic decisions should be guided by a multidisciplinary geriatric assessment, allowing a complete assessment of physical and functional performance. In this context, the GERABEL study aimed to orientate the irradiation strategy based on a detailed oncogeriatric assessment in women more than 70 years old with breast cancer.

Materials and methods: This was a multicentre clinical trial conducted between January 2017 and June 2021. The oncogeriatric assessment comprised seven questionnaires (activities of daily living [ADL], instrumental ADL, Mini-Mental State Examination, mini Geriatric Depression Scale, Mini-Nutritional Assessment, Cumulative Illness Rating Scale-Geriatric, and Timed Up and Go) to determine a predictive score. Irradiation regimen was assigned according to oncogeriatric score: normofractionated - NF (score range, 160-200), hypofractionated - HF (score range, 159-120), or high-dose hypofractionated - HDHF (score ≤ 119). Endpoints were the overall tolerance to treatment, using the oncogeriatric score as a proxy at six months post-treatment, and compliance.

Results: After oncogeriatric assessment at baseline, 177 patients were treated with a NF regimen, 24 with a HF regimen, and four with a HDHF regimen. Tolerance was excellent in the three groups, as no decrease of more than 20 % in the oncogeriatric score was noted at six months post-treatment. More generally, 68 % and 73 % of patients reported an improvement of the oncogeriatric score at two months and six months post-treatment, respectively. Only four treatment interruptions were observed and quality-of-life was well-conserved. In the hypo fractionated groups, short-term toxicities were not increased and no impact was noted on compliance.

Discussion: Decision-making guidance for irradiation schemes in breast cancer according to oncogeriatric determinants was successful in older patients, who tolerated treatment well and, overall, had a preserved general condition.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of geriatric oncology
Journal of geriatric oncology ONCOLOGY-GERIATRICS & GERONTOLOGY
CiteScore
5.30
自引率
10.00%
发文量
379
审稿时长
80 days
期刊介绍: The Journal of Geriatric Oncology is an international, multidisciplinary journal which is focused on advancing research in the treatment and survivorship issues of older adults with cancer, as well as literature relevant to education and policy development in geriatric oncology. The journal welcomes the submission of manuscripts in the following categories: • Original research articles • Review articles • Clinical trials • Education and training articles • Short communications • Perspectives • Meeting reports • Letters to the Editor.
期刊最新文献
Systemic and procedural challenges in transitioning patients with cancer to post-acute and long-term care facilities: A prospective mixed-methods study. The role of healthcare professionals' attitudes in treatment decision-making for older adults with cancer: A scoping review. "Start low, go slow," a strategy to tailor treatment dosing in older or vulnerable adults with advanced solid cancer: A systematic review and meta-analysis. Age disparities in clinical trials of poly (ADP-ribose) polymerase (PARP) inhibitors in patients with high grade serous ovarian cancer: A wake up call to improving outcomes in older patients. Effects of dementia on functional decline in patients with non-small cell lung cancer at discharge from acute care hospitals: A retrospective cohort study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1